[ Diretor: Mário Frota [ Coordenador Editorial: José Carlos Fernandes Pereira [ Fundado em 30-11-1999 [ Edição III [ Ano XII

quinta-feira, 6 de abril de 2017

Europe’s biotechnology potential hindered by investment fears

The EU is lagging behind the US in the biotechnology sector due to challenges in translating scientific innovations into successful businesses.
[HCC Public Information Office/Flickr]
Despite the EU’s consistent growth in the biotech business, the EBE claims that the industry is not receiving enough support from investors, universities or research institutions, thus limiting the EU’s ability to keep pace with the US in biotechnology.

The EU is lagging behind due to challenges in translating scientific innovations into successful businesses, a European Biopharmaceutical Enterprises (EBE) report claims.

Biotechnology is the use of living systems or organisms in the creation of industrial products. The growth of the biotechnology industry is “important for Europe” and created 10,000 new jobs and 93 medicines recommended for market authorisation by the European Medical Agency in 2015, according to the EBE.

Biotechnology in Europe

Biotechnology could help patients across Europe gain access to innovative therapies, for example, against rare diseases. Proponents of bio-medicines also claim that precision therapy, because it is more efficient, will ease the burden on member states’ ailing healthcare systems.


The EBE suggests that steps should be taken to create a stronger investor community for biotech products to prevent places other than Europe from benefitting economically from technology invented and developed in Europe.

“License to fail”

Sem comentários: